(Total Views: 361)
Posted On: 12/17/2018 3:09:06 PM
Post# of 72436
good point Drano
For this reasons most of the P3 randomize clinical trials (RCT's) have crossover design so the patients in control (placebo) arm can be moved to "real" drug arm upon progression or in this case development of severe OM
I am sure IPIX will do mid-term analysis to establish efficacy of B-OM in the middle of accrual period and if compeling results to close the trial much early
IMO
cheers
For this reasons most of the P3 randomize clinical trials (RCT's) have crossover design so the patients in control (placebo) arm can be moved to "real" drug arm upon progression or in this case development of severe OM
I am sure IPIX will do mid-term analysis to establish efficacy of B-OM in the middle of accrual period and if compeling results to close the trial much early
IMO
cheers
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)